Advertisement
Person › Details
Judith Gréciet (BioAlliance Pharma S.A.)
Gréciet, Judith (BioAlliance Pharma 201306 CEO + France Biotech 201508 Board Member)
Organisation | BioAlliance Pharma S.A. | |
Today | Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO) | |
Group | Onxeo (Group) | |
Former/major organisation | France Biotech | |
Product | Livatag® | |
Product 2 | Validive® | |
Record changed: 2018-08-03 |
Advertisement
More documents for Judith Gréciet
- [1] Onxeo S.A.. (7/27/18). "Press Release: Onxeo Reports Half-Year 2018 Financial Results and Provides Business Outlook". Paris....
- [2] Onxeo S.A.. (4/24/18). "Press Release: Onxeo Announces Initiation of DRIIV Phase I Clinical Trial of AsiDNA for Treatment of Advanced Solid Tumor". Paris....
- [3] Roche. (9/11/17). "Press Release: Onxeo Announces Top-line Results from ReLive Phase III Study of Livatag in Advanced Hepatocellular Carcinoma". Paris....
- [4] Onxeo S.A.. (6/20/17). "Press Release: Onxeo Successfully Raises €15 Million with US and European Investors [Not for distribution in the United States, Canada, Australia and Japan]". Paris....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top